| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13519 R52243 |
Fitton - Calcium Blockers, 2021 | Circulatory defects (Q20-Q28) | during pregnancy (anytime or not specified) excluded | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
1.46 [0.11;19.13] excluded (exposition period) |
-/- 873/252,598 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14252 R56029 |
Fisher - Calcium blockers (Controls unexposed, disease free), 2017 | Any Congenital Heart Defects | early pregnancy | case control | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
1.41 [0.65;3.05] excluded (control group) |
18/29 10,607/21,733 | 10,625 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14253 R56037 |
Fisher - Calcium blockers (Controls unexposed, sick), 2017 | Any Congenital Heart Defects | early pregnancy | case control | unexposed, sick | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.30 [0.59;2.86] | 18/29 -/- | - | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13439 R51783 |
Lennestal - Calcium inhibitors, 2009 | Any cardiovascular defect | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.15 [0.24;3.35] | 3/217 12,660/1,046,843 | 12,663 | 217 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13996 R54983 |
Sorensen - Calcium blockers, 2001 | Cardiovascular congenital abnormality | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.60 [0.80;3.20] | 9/58 4,458/42,560 | 4,467 | 58 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.42 [0.87;2.30] | 17,130 | 304 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 14252